Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego

Detalhes bibliográficos
Autor(a) principal: Santos, Liani Patricia Andrade [UNIFESP]
Data de Publicação: 2021
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=11334890
https://repositorio.unifesp.br/handle/11600/68231
Resumo: Prospective, double-blind and randomized pilot study to compare the effectiveness of oxytocin (OT) in relation to promestriene in improving sexual function, symptoms of vaginal atrophy as well as the clinical and histopathological examination of the vaginal wall in Genitourinary Syndrome of Menopause (GSM). 51 postmenopausal women presenting symptoms of GSM who met the inclusion and exclusion criteria were evaluated. They were randomized into two groups: group 1 (OT) with 25 patients and group 2 (promestriene) with 26. Patients received vaginal OT or promestriene gel and the FSFI domains (lubrication, satisfaction, and pain in sexual intercourse), visual clinical examination and vaginal wall thickness were evaluated before and after 90 days of treatment. Both groups, after the use of the medications showed significant improvement of the three FSFI domains evaluated (p<0.05). And when compared, no differences were revealed (p>0.05). However without statistical significance (p>0.05), the medications presented improvement in all parameters evaluated in the clinical examination. In the evaluation of the thickness of the vaginal epithelium, both treatments, when evaluated separately, presented an increase of the vaginal epithelium after their use however promestriene revealed better effectiveness than OT (p<0.05). Conclusion: After 90 days of vaginal application of oxytocin and promestriene, both were conformably effective in improving lubrication, satisfaction and pain domains obtained from the FSFI score, with no significant variance between them; Even without statistical significance, alterations in the vaginal mucosa visualized on clinical examination were improved; they were effective in increasing the thickness of the vaginal epithelium, with the promestriene showing superior performance. Yet, studies with a longer sample and prolonged time are still necessary to confirm clinical applicability.
id UFSP_592bf5fe78b4406d45c0c0592f321dc1
oai_identifier_str oai:repositorio.unifesp.br/:11600/68231
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cegoGenitourinary SyndromePromestrieneOxytocinVulvovaginal AtrophyMenopauseSindrome GeniturináriaPromestrienoOcitocinaAtrofia VulvovaginalMenopausaProspective, double-blind and randomized pilot study to compare the effectiveness of oxytocin (OT) in relation to promestriene in improving sexual function, symptoms of vaginal atrophy as well as the clinical and histopathological examination of the vaginal wall in Genitourinary Syndrome of Menopause (GSM). 51 postmenopausal women presenting symptoms of GSM who met the inclusion and exclusion criteria were evaluated. They were randomized into two groups: group 1 (OT) with 25 patients and group 2 (promestriene) with 26. Patients received vaginal OT or promestriene gel and the FSFI domains (lubrication, satisfaction, and pain in sexual intercourse), visual clinical examination and vaginal wall thickness were evaluated before and after 90 days of treatment. Both groups, after the use of the medications showed significant improvement of the three FSFI domains evaluated (p<0.05). And when compared, no differences were revealed (p>0.05). However without statistical significance (p>0.05), the medications presented improvement in all parameters evaluated in the clinical examination. In the evaluation of the thickness of the vaginal epithelium, both treatments, when evaluated separately, presented an increase of the vaginal epithelium after their use however promestriene revealed better effectiveness than OT (p<0.05). Conclusion: After 90 days of vaginal application of oxytocin and promestriene, both were conformably effective in improving lubrication, satisfaction and pain domains obtained from the FSFI score, with no significant variance between them; Even without statistical significance, alterations in the vaginal mucosa visualized on clinical examination were improved; they were effective in increasing the thickness of the vaginal epithelium, with the promestriene showing superior performance. Yet, studies with a longer sample and prolonged time are still necessary to confirm clinical applicability.Estudo piloto prospectivo, duplo-cego e randomizado para comparar a eficácia da ocitocina (OT) em relação ao promestrieno na melhora da função sexual, dos sintomas de atrofia vaginal, do exame clínico e histopatológico da parede vaginal na Síndrome Geniturinária da Menopausa (GSM). Foram avaliadas 51 mulheres na pós-menopausa apresentando sintomas da GSM e que satisfaziam os critérios de inclusão e exclusão. Foram randomizados em dois grupos: grupo 1 (OT) com 25 pacientes e grupo 2 (promestrieno) com 26. As pacientes recebiam gel vaginal de OT ou promestrieno e os domínios do FSFI (lubrificação, satisfação e dor na relação sexual), o exame clínico visual e a espessura da parede vaginal eram avaliados antes e após 90 dias de tratamento. Ambos os grupos, após o uso das medicações mostraram melhora significante dos três domínios do FSFI avaliados (p<0,05) e quando comparados, não revelaram diferença (p>0,05). No exame clínico, as medicações revelaram melhora em todos os parâmetros avaliados, porém sem significância estatística (p>0,05). Na avaliação da espessura do epitélio vaginal ambos os tratamentos, quando avaliados separadamente, mostraram aumento após as medicações (p< 0,05), porém o promestrieno revelou melhor eficácia que a OT (p<0,05). Conclusão: Após 90 dias da aplicação vaginal da ocitocina e do promestrieno, concluímos que ambos foram eficazes, sem diferença significante entre eles, na melhora dos domínios lubrificação, satisfação e dor obtidos do escore FSFI; promoveram melhora das alterações da mucosa vaginal visualizadas ao exame clínico, porém sem significância estatística; foram eficazes para o aumento da espessura do epitélio vaginal, havendo superioridade do promestrieno. No entanto, estudos com maior casuística e por tempo prolongado ainda são necessários para confirmar a aplicabilidade clínica.Dados abertos - Sucupira - Teses e dissertações (2021)Universidade Federal de São Paulo (UNIFESP)Silva, Ismael Dale Cotrim Guerreiro Da [UNIFESP]Universidade Federal de São PauloSantos, Liani Patricia Andrade [UNIFESP]2023-06-27T12:32:41Z2023-06-27T12:32:41Z2021info:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/publishedVersion50 p.application/pdfhttps://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=11334890LIANI PATRICIA ANDRADE SANTOS-A.pdfhttps://repositorio.unifesp.br/handle/11600/68231porinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-12T22:10:15Zoai:repositorio.unifesp.br/:11600/68231Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-12T22:10:15Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego
title Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego
spellingShingle Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego
Santos, Liani Patricia Andrade [UNIFESP]
Genitourinary Syndrome
Promestriene
Oxytocin
Vulvovaginal Atrophy
Menopause
Sindrome Geniturinária
Promestrieno
Ocitocina
Atrofia Vulvovaginal
Menopausa
title_short Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego
title_full Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego
title_fullStr Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego
title_full_unstemmed Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego
title_sort Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego
author Santos, Liani Patricia Andrade [UNIFESP]
author_facet Santos, Liani Patricia Andrade [UNIFESP]
author_role author
dc.contributor.none.fl_str_mv Silva, Ismael Dale Cotrim Guerreiro Da [UNIFESP]
Universidade Federal de São Paulo
dc.contributor.author.fl_str_mv Santos, Liani Patricia Andrade [UNIFESP]
dc.subject.por.fl_str_mv Genitourinary Syndrome
Promestriene
Oxytocin
Vulvovaginal Atrophy
Menopause
Sindrome Geniturinária
Promestrieno
Ocitocina
Atrofia Vulvovaginal
Menopausa
topic Genitourinary Syndrome
Promestriene
Oxytocin
Vulvovaginal Atrophy
Menopause
Sindrome Geniturinária
Promestrieno
Ocitocina
Atrofia Vulvovaginal
Menopausa
description Prospective, double-blind and randomized pilot study to compare the effectiveness of oxytocin (OT) in relation to promestriene in improving sexual function, symptoms of vaginal atrophy as well as the clinical and histopathological examination of the vaginal wall in Genitourinary Syndrome of Menopause (GSM). 51 postmenopausal women presenting symptoms of GSM who met the inclusion and exclusion criteria were evaluated. They were randomized into two groups: group 1 (OT) with 25 patients and group 2 (promestriene) with 26. Patients received vaginal OT or promestriene gel and the FSFI domains (lubrication, satisfaction, and pain in sexual intercourse), visual clinical examination and vaginal wall thickness were evaluated before and after 90 days of treatment. Both groups, after the use of the medications showed significant improvement of the three FSFI domains evaluated (p<0.05). And when compared, no differences were revealed (p>0.05). However without statistical significance (p>0.05), the medications presented improvement in all parameters evaluated in the clinical examination. In the evaluation of the thickness of the vaginal epithelium, both treatments, when evaluated separately, presented an increase of the vaginal epithelium after their use however promestriene revealed better effectiveness than OT (p<0.05). Conclusion: After 90 days of vaginal application of oxytocin and promestriene, both were conformably effective in improving lubrication, satisfaction and pain domains obtained from the FSFI score, with no significant variance between them; Even without statistical significance, alterations in the vaginal mucosa visualized on clinical examination were improved; they were effective in increasing the thickness of the vaginal epithelium, with the promestriene showing superior performance. Yet, studies with a longer sample and prolonged time are still necessary to confirm clinical applicability.
publishDate 2021
dc.date.none.fl_str_mv 2021
2023-06-27T12:32:41Z
2023-06-27T12:32:41Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=11334890
LIANI PATRICIA ANDRADE SANTOS-A.pdf
https://repositorio.unifesp.br/handle/11600/68231
url https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=11334890
https://repositorio.unifesp.br/handle/11600/68231
identifier_str_mv LIANI PATRICIA ANDRADE SANTOS-A.pdf
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 50 p.
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
publisher.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268454763495424